Objective/Hypothesis: Ineffective mucociliary clearance (MCC) is a common pathophysiologic process that underlies airway inflammation and infection. A dominant fluid and electrolyte secretory pathway in the nasal airways is governed by the cystic fibrosis transmembrane conductance regulator (CFTR). Decreased transepithelial Cl 2 transport secondary to an acquired CFTR deficiency may exacerbate respiratory epithelial dysfunction by diminishing MCC and increasing mucus viscosity. The objectives of the present study are to 1) develop a model of acquired CFTR deficiency in sinonasal epithelium using hypoxia, 2) investigate whether the polyphenol resveratrol promotes CFTR-mediated anion transport, 3) explore resveratrol mechanism of action and determine therapeutic suitability for overcoming acquired CFTR defects, and 4) test the drug in the hypoxic model of acquired CFTR deficiency in preparation for a clinical trial in human sinus disease. We hypothesize that hypoxia will induce depletion of airway surface liquid (ASL) secondary to acquired CFTR deficiency and that resveratrol will restore transepithelial Cl 2 secretion and recover ASL hydration. Study Design: Basic science. Methods: Murine nasal septal (MNSE) and human sinonasal epithelial (HSNE) cultures were incubated under hypoxic conditions (1% O 2 , 5% CO 2 ) and transepithelial ion transport (change in short-circuit current 5 DI SC ) evaluated in Ussing chambers. Resveratrol was tested using primary cells and HEK293 cells expressing human CFTR by Ussing chamber and patch clamp techniques under both phosphorylating and nonphosphorylating conditions. CFTR activation was evaluated in human explants and by murine in vivo (nasal potential difference) assessment. Cellular cyclic adenosine monophosphate (cAMP) (ELISA) and subsequent CFTR regulatory domain (R-D) phosphorylation (gel-shift assay) were also evaluated. Effects of hypoxia and resveratrol on ASL were tested using confocal laser scanning microscopy (CLSM) and micro-optical coherence tomography (mOCT).
INTRODUCTION
Chronic rhinosinusitis (CRS) causes significant morbidity and detriments to quality of life for 16% of the U.S. population and accrues an estimated aggregated cost of 8.6 billion dollars annually in health care expenditures. [1] [2] [3] Patients with CRS mark worse scores for physical pain and social functioning on quality-of-life questionnaires than those suffering from chronic obstructive pulmonary disease, congestive heart failure, or angina. 2 Conventional CRS treatments are comprised of antibiotics, steroids, and surgical intervention. New therapies using safe but effective compounds that either augment the benefit of current treatments or target inherent properties of sinonasal mucosa are clearly needed.
Normal sinonasal mucociliary function is a critical host defense mechanism that clears the upper airways of inhaled pathogens such as bacteria, dust, and aerosols. Sinonasal respiratory epithelium is a highly regulated barrier that is central to function of the mucociliary apparatus. Mucociliary clearance (MCC) is dependent on inherent biological properties of intact respiratory epithelium, including proper ciliary beating and the airway surface liquid (ASL). The ASL is composed of a periciliary fluid (sol) layer and a mucus (gel) layer. 4 Respiratory epithelium modifies the volume of the periciliary fluid layer 5 and the viscoelastic properties of the mucus in a fashion that depends on vectorial transepithelial ion transport. 6, 7 The active and passive transport of electrolytes (primarily sodium [Na 1 ], chloride [Cl 2 ], and bicarbonate [HCO 3 2 ]) modulate ASL, and significant alterations in ion transport can be detrimental to the airway, as clearly exemplified by the disease cystic fibrosis (CF), which fibrosis affects approximately 30,000 persons in the United States (70,000 worldwide) and is the most common lethal inherited disease among Caucasians. 8 In CF, mutations in the gene encoding CFTR result in decreased apical membrane anion conductance and cause dysregulated Na 1 absorption. 8 These abnormalities of fluid and electrolyte transport promote thick mucus formation and immobile exocrine secretions in multiple organ systems. In the sinuses of CF individuals, chronic stasis of inspissated mucus in combination with bacterial infection result in nearly universal inflammatory paranasal sinus disease.
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The CFTR is a member of the ATP-binding cassette protein family and is comprised of multiple domains, including two transmembrane domains (TMs) and two nucleotide binding domains (NBDs). In addition, CFTR has a single regulatory domain (R-D) that functions in part to control CFTR activity. 13 Activation of CFTR is thought to occur by a two-step process that involves 1) phosphorylation of the R-D, and 2) dimerization of the two NBDs, facilitating ATP binding and activation of the Cl 2 channel by inducing a conformational change in the TMs. Clinically important mutations in the CFTR gene can affect transcription, translation, posttranslational modification, channel gating and function, and protein stability and turnover at the plasma membrane. The most common cause of CF is due to the deletion of phenylalanine at CFTR position 508 (F508del CFTR), which results in misfolding of the protein product in the endoplasmic reticulum and accelerated degradation by the proteosome. The absence of CFTR at the plasma membrane results in defective ion transport and the clinical manifestations of CF. 13 Other mutations, such as G551D, result in adequate levels of CFTR protein at the apical cell surface, but the channels exhibit defective gating. 14 The genetic mutations in individuals afflicted with CF contribute to phenotypic expression of the disease. However, recent evidence indicates that wild-type (WT) CFTR processing, endocytic recycling, and function can also be markedly repressed by various environmental insults, including cigarette smoke exposure, high altitude/hypoxemia, inflammation, and infectious agents, and may be a contributing factor in CRS and other disease of MCC such as chronic obstructive pulmonary disease (COPD). [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Hypoxia has been suggested to have considerable influence in the pathophysiology of CRS among non-CF individuals. [25] [26] [27] Blockage of sinus ostia may lead to hypoxia, resulting in decreased MCC, elaboration of inflammatory mediators, and bacterial colonization. 27 In addition, accumulated secretions and impacted mucus lead to poor oxygen (O 2 ) delivery, resulting in near anaerobic tissue conditions that accelerate progression of disease. 28 Aaneas et al. 29 used an oxygen probe to cannulate the maxillary sinuses of CF patients with CRS and found severely repressed pO 2, including some individuals with complete anoxia. Hypoxia in the sinuses of CRS patients could contribute to propagation of sinus disease by creating a localized CFTR-deficient environment where abnormalities of fluid and electrolyte transport persist. In either case, a strategy aimed at stimulating electrolyte secretion with drugs that target CFTR, therefore promoting mucus clearance, would furnish a valuable addition to the pharmacologic armamentarium available for treatment of sinusitis.
Several small organic molecules that activate CFTR have been identified through high-throughput screening of compound libraries containing millions of discrete agents. Pharmaceutical companies have pursued CFTR potentiators for therapy of diseases of mucus clearance, including both CF and COPD. One such agent, ivacaftor (Vertex Phamaceuticals, Boston MA), represents a novel CF therapeutic recently approved for treatment of CF patients with at least one copy of the G551D mutation. 30 In this CF population, ivacaftor improves CFTR channel opening and thereby augments endpoints predictive of benefit, including MCC, sweat Cl 2 , and lung function. 31 Importantly, the same strategy being applied to activate Cl 2 secretion in the lower airways of CF patients is also applicable to impaired sinus and nasal mucus clearance. 31 Mechanistically, ivacaftor increases channel open probability (Po) in both G511D mutated and WT CFTR in the presence of R-D phosphorylation. This is best demonstrated in vitro following activation of cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA)-dependent pathways by drugs such as forskolin that confer phosphorylation of the R-D. 32 Other compounds such as the flavonoid, genistein, increase CFTR channel Po by enhancing channel-open time and decreasing closed time, a phenomenon also observed as decreased rundown of CFTR channels studied by membrane patch excision. 33, 34 Flavonoid compounds related to genistein also exhibit the capacity to activate CFTR Po, [35] [36] [37] particularly after forskolin-mediated phosphorylation. 38 Based on these and other functional studies, several laboratories have concluded that flavonoids may directly bind to CFTR, possibly at the interface between the two NBDs. 39, 40 Other molecules identified by high throughput compound library screening, such as the isoxazole UC CF 2152 (3-[2-bezyloxy-phenyl]-5-chloromethyl-isoxazole), induce PKA-dependent phosphorylation of the R domain. 41 In summary, multiple agents are known to activate CFTR Cl 2 transport by a variety of distinct mechanisms and are therefore candidates for targeting basal CFTR activity and acquired ion transport defects that underlie pathogenesis in CRS.
Resveratrol is an organic polyphenol found in many plants and vegetables, including the skins of red fruits, trees, some flowering plants, and peanuts. 42, 43 Flavonoids are also plant-based compounds that possess the common flavone ring structure (2-phenyl-c-benzopyrone). 38 Resveratrol lacks the central ring of the common three-ring flavone backbone but is otherwise structurally similar to flavonoids as a polyphenolic molecule. Broadly recognized for its immune-modulator activity attributable to inhibition of NF-jB signaling, 44 resveratrol markedly reduces inflammatory pathways mediated by granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-8 (or the murine homologue KC), inducible nitric oxide synthase, and COX-2. 44 However, utility as a therapeutic agent for acquired CFTR dysfunction in sinus disease has not been previously investigated.
The objectives of the current study were to 1) use oxygen restriction to create a model of acquired CFTR deficiency in sinonasal epithelium; 2) investigate whether the polyphenol resveratrol stimulates CFTR-mediated anion transport in vitro, ex vivo, and in vivo; 3) explore the mechanistic action of resveratrol on CFTR function and activity in sinonasal epithelium to determine therapeutic suitability for acquired CFTR defects in human sinus disease; and 4) test the drug in the hypoxic model of acquired CFTR deficiency in preparation for a clinical trial of mucociliary activators in human sinus disease. We hypothesize that hypoxia induces the depletion of ASL secondary to alterations in transepithelial ion transport in a similar fashion to CF disease, and that the impact of the environmental hypoxic insult can be ameliorated through the application of resveratrol.
MATERIALS AND METHODS
University of Alabama at Birmingham Institutional Animal Care and Use Committee and Institutional Review Board (IRB) approval were obtained prior to initiation of the study. Written informed consent was obtained from each participant on a document approved by the IRB.
Tissue Culture
Primary sinonasal epithelial cells (from humans, mice, and pigs) were cultured at an air-liquid interface according to previously established protocols. [45] [46] [47] [48] [49] [50] [51] [52] [53] All of the murine nasal septal epithelial (MNSE) cells were obtained from congenic C57/ BL6 WT and CFTR 2/2 mice. Primary human sinonasal epithelial (HSNE) cells were prepared and cultured on collagen-coated Costar 6.5-mm-diameter permeable filter supports (Corning, Lowell, MA) submerged in culture media. Differentiation and ciliogenesis occurred in all cultures within 10 to 14 days. All experiments were performed only when cell monolayers were fully differentiated with widespread ciliogenesis and transepithelial resistances (R t ) > 300 X. cm 2 . A recombinant human CFTR-expressing HEK293 cell line (D060) was also employed for patch clamp analysis. 54 For hypoxia experiments, cells were incubated in a sealed modular incubator chamber at 378C, with an environment comprised of a 1% O 2 , 5% CO 2 (the remainder consisting of nitrogen), or a physiologic environment (21% O 2 , 5% CO 2 ).
Electrophysiology
Ussing Chamber Short Circuit (I SC ) Measurements. To investigate pharmacologic manipulation of vectorial ion transport, a large array of electrophysiology assays were employed. Human sinonasal epithelial explants were removed from patients undergoing endoscopic surgery for pituitary tumor, benign sinonasal tumor, or cerebrospinal fluid leak repair. Specimens were immediately stored in ice-cold DMEM/F-12 media (Invitrogen, Grand Island, NY, USA) and transferred to the laboratory within 15 minutes. A thin layer of epithelial tissue was dissected from the surgical specimen, placed on a slider with an open area of 0.031-to 0.71-cm 2 , and mounted between Ussing-type hemichambers (Easy Mount, Physiologic Instruments Inc., San Diego, CA) to evaluate resveratrol activity ex vivo. Transwell inserts containing monolayers as well as tissues were arranged in Ussing chambers (VCC 600; Physiologic Instruments Inc.) and continuously analyzed under short-circuit conditions following fluid resistance compensation using automatic voltage clamps. Bath solutions for the transwell filters were warmed to 378C, and each sample continuously gas lifted with 95% O 2 to 5% CO 2 or 94% N 2 /1%O 2 /5% CO 2 mixture for hypoxia experiments. The bath solution contained (mM): 120 NaCl, 25 NaHCO 3 , 3.3 KH 2 PO 4 , 0.8 K 2 HPO 4 , 1.2 MgCl 2 , 1.2 CaCl 2 , and 10 glucose with pH 7.3 to 7.4. Chemicals were acquired from Sigma (St. Louis, MO). Each solution was formulated as 10003 stock and used at 13 in the Ussing chamber. All experiments were performed with low Cl 2 (6 mM) in the mucosal bath. Pharmacologic preparations were the following: amiloride (100 mM), ivacaftor (10 mM), forskolin (20 mM), and INH-172 (10 mM). Resveratrol (trans isoform) was utilized at a range of doses to establish a working concentration. Amiloride blocks epithelial sodium (Na 1 ) channels and supports the notion that variation in short-circuit current (DI SC ) from subsequent manipulation is due to effects on Cl 2 channel activity. Forskolin stimulates the cystic fibrosis transmembrane conductance regulator via cAMP-mediated/PKA-dependent phosphorylation of the R-D, as described above. INH-172 is a selective inhibitor of CFTR and aids in determining the degree of contribution of CFTR to the I SC under experimental conditions. Corresponding DMSO (vehicle) control solutions for resveratrol and ivacaftor were studied in parallel. The I SC was assessed at one current measurement per second. By convention, a positive deflection in I SC was defined as the net movement of anions in the serosal to mucosal direction.
Single-Channel Studies. Conventional patch clamp techniques were adapted to record single-channel currents by cellattached and inside-out configuration using MNSE and HEK293 cells expressing WT human CFTR. Recording pipettes were constructed from borosilicate glass capillaries (Warner Instruments, Hamden CT) using a Narishige PP83 microelectrode puller and fire polished with a PP90 microforge (Narishige, Tokyo, Japan). The pipettes were partially filled with a solution containing (in mmol/l) 150 CsCl, 1 CaCl 2 , 1 MgCl 2 and 10 HEPES (pH 7.2), with tip resistances of 6 to 8 MX. All experiments were performed at room temperature (20-228C). Single-channel currents were obtained using an Axopatch 200B patch clamp amplifier (Axon Instruments, Molecular Devices, Sunnyvale, CA), with voltage commands and data acquisition controlled by Clampex software (pClamp 10, Axon Instruments) and digitized (Digidata 1440A interface, Axon Instruments) at a sampling frequency of 1 kHz. MNSE or HEK293 cells seeded on glass coverslips were mounted in a flow-through chamber. To acquire seals, bath solutions contained (in mmol/l) 140 NaCl, 4.0 KCl, 1.8 CaCl 2 , 1.0 MgCl 2 , 10 glucose, and 10 HEPES pH 7.4. For inside-out patches, bath solution was comprised of (in mmol/l) 150 CsCl, 5 EDTA, and 10 HEPES pH 7.4 designed to minimize channel rundown. Resveratrol was used at a working concentration of 100 mM. Vehicle controls were included in all studies (DMSO 0.02%). Confirmation that stimulated currents were due to CFTR activity was achieved using the inhibitor INH-172 at 10 mM. Single-channel recordings were analyzed using pClamp 10 software where Vcom 5 command potential (Axon Instruments). Tracings were filtered postacquisition at 500 Hz.
Nasal Potential Difference Assay. A 3-step protocol was used, as described previously. 55 Animals were anesthetized with ketamine (200 mg/kg), acepromazine (0.6 mg/kg), and xylazine (30 mg/kg) by intraperitoneal injection prior to testing. First, nasal cavities of anesthetized mice (C57/BL6) were perfused sequentially with 1) Ringer's solution containing 140 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 2 mM CaCl 2 , 10 mM HEPES, and amiloride 50 lM (pH 7.3); 2) amiloride 1 a low-Cl secretion rather than Na 1 absorption. Each condition was studied for 5 to 10 minutes until a steady signal was achieved. Activity of the test solution was measured from the stable baseline to the highest point of hyperpolarization. All traces were interpreted in a blinded fashion.
CFTR R-D Phosphorylation and cAMP Levels
Because activation of CFTR-mediated anion transport requires PKA-dependent phosphorylation of the R-D, an ELISAbased detection kit (Cayman Chemicals, Ann Arbor, MI) was used to measure stimulation of cellular cAMP by resveratrol in MNSE cultures, as previously described. 56, 57 To confirm absence of a cAMP/PKA dependent mechanism, polyclonal NIH-3T3 cells expressing HA-tagged R-D were treated with resveratrol for 20 minutes and compared to forskolin (20 mM) 3 5 minutes as a positive control and to DMSO as a negative control. Following lysis, equal amounts (50 mg) of total cell lysate were electrophoresed through a 12% sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) and immunoblotted with antibody to the HA tag (Covance, Cumberland, VA). Phosphorylation of the R-D was visualized as a 2 to 4 kD shift in migration, as previously described. 56 Airway Surface Liquid Depth Confocal Laser Scanning Microscopy. Cells were washed three times with PBS followed by administration of 100 lM CellTracker Green BODIPY (Invitrogen, cat. no.: C2102) to the basolateral medium and 10 mg/ml Texas Red (Invitrogen, cat. no.: D-1863) in FC-70 (Flourinert FC-70, Fisher, cat. no.: NC 9062226) to the apical side 2 hours before confocal visualization. Cells incubated at 1% O 2 /5% CO 2 were compared to physiologic O2 (air control). Resveratrol, resveratrol 1 INH2172 (10 mM), or vehicle (DMSO) control were added to apical (in 30-ml volume) chambers, and imaging was performed with a Zeiss LSM 710 Confocal Microscope (Oberkochen, Germany) using Zeiss Plan Apo 203 .8 na dry objective in 1-micron steps. Airway surface liquid (ASL) depth was measured in the orthogonal (head on X-Z) image view. Two regions of interest were analyzed for each monolayer, and average ASL depth was measured for five equally distributed locations in each region.
Statistical Analysis
Statistical analyses were conducted using Excel 2010 (Microsoft Corp., Redmond, WA) and GraphPad Prism 6.0 software (GraphPad Prism, La Jolla, Ca) with significance set at P < 0.05. Statistical evaluation utilized paired and unpaired Student t tests, the Mann-Whitney rank sum test, or the analysis of variance followed by Tukey-Kramer multiple comparison test, as appropriate.
RESULTS

Hypoxic Primary Sinonasal Epithelial Cultures Are a Valid In Vitro Model of Acquired CFTR Deficiency
In order to establish and confirm the validity of hypoxia-induced acquired CFTR deficiency, MNSE and HSNE cultures were incubated for 12 and 24 hours at 1% O 2 and evaluated in Ussing chambers using pharmacologic manipulation. The change in short-circuit current (DI SC 5 mA/cm 2 ) attributable to CFTR (forskolin-stimulated transport) was significantly decreased at 12 and 24 hours in MNSE (Fig. 1A, 1B Similar to MNSE, forskolin-stimulated DI SC in HSNE ( Fig. 2A, 2B) 
Hypoxia Depletes Airway Surface Liquid
To assess whether the ion transport deficiencies observed in the Ussing chamber would confer abnormalities of ASL, hypoxic MNSE were evaluated at 24 hours by CLSM and the mOCT techniques. ASL depth was decreased under hypoxic conditions when measured by CLSM (in mm: 4.19 6 0.44, hypoxia; 6.88 6 0.67, n 5 per condition, control; P < 0.05) providing direct evidence that altered ion transport in this culture model leads to ASL depletion (Fig. 3) .
Resveratrol Is a Robust CFTR-Dependent Cl
2
Secretagogue
Following confirmation of our model of hypoxiainduced CFTR deficiency, a comprehensive evaluation of resveratrol was implemented to assess its utility as a Cl 2 secretagogue in sinonasal epithelium. Dosedependent CFTR-mediated anion transport (DI SC ) was analyzed using MNSE cultures in Ussing chambers. Resveratrol activated CFTR-mediated Cl 2 conductance in a dose-dependent fashion up to 500 mM, but it demonstrated modest inhibitory effects on total CFTR activation with posttreatment forskolin (100 nM) at concentrations > 100 mM (Fig. 4A and 4B) 63 ). CFTR 5 cystic fibrosis transmembrane conductance regulator; HSNE 5 human sinonasal epithelial; MNSE 5 murine nasal septal. Fig. 1 . Hypoxia induces acquired defects in transepithelial ion transport in murine nasal epithelia. Murine nasal septal cells grown on transwell permeable supports and incubated in 1% O 2 or physiologic O 2 (control, 21%) for 12 or 24 hours were mounted in Ussing chambers under short-circuit conditions and sequentially exposed to amiloride (100 mM), forskolin (20 mM), and INH-172 (10 mM). Representative tracings (at 24 hours) are shown in (A). By convention, a positive deflection in the tracing represents movement of anion in the serosal to mucosal direction. Summary data is represented in (B). Under these conditions, change in short-circuit current (DI SC ) was significantly decreased at all time points with amiloride (used as a means to monitor epithelial sodium channels) and forskolin (a pharmacologic activator of CFTR). CFTR blockade by INH-72 was also significantly decreased compared to control (n 6 per condition). (Adapted from Blount et al. 63 ). CFTR 5 cystic fibrosis transmembrane conductance regulator. P < 0.05) was considered an optimal dose for subsequent studies. CFTR 2/2 knockout MNSE on the same genetic background were used to confirm that resveratrolstimulated DI SC is mediated through a CFTR-dependent mechanism (Fig. 4C) . Following application of amiloride, resveratrol (100 mM) resulted in no measurable transepithelial secretion; therefore, no contribution from alternative Cl 2 transport pathways (i.e., calcium-activated Cl (Fig. 5A and 5B). Resveratrol activated between 50% and 70% of total CFTR-dependent I SC , as judged by addition of saturating (20 mM) forskolin (murine 22.0 6 1.8, human 29.4 6 1.5, and porcine 14.2 6 0.2). The drug produced equivalent levels of CFTR-mediated anion transport when compared to ivacaftor (16.5 6 1.9 at an optimal concentration of 10 mM) in human sinonasal epithelial cultures (Fig. 5C ).
Resveratrol Activates Human Sinonasal CFTRMediated Cl 2 Transport Ex Vivo
Once in vitro evaluation was confirmed, activity in freshly excised sinus tissue from individuals undergoing endoscopic sinus surgery was performed (n 5 5; paired samples) (Fig. 6A and 6B 
Secretion Across In Vivo Murine Nasal Epithelium
To establish resveratrol's capabilities to activate Cl 2 transport in nasal epithelium in vivo, the murine nasal potential difference assay was utilized. Mice perfused with resveratrol (100 uM) in the presence of amiloride (100 mM) and a Cl 2 secretory gradient demonstrated significant hyperpolarization (24 6 1.87 mV) compared with continued depolarization seen in mice perfused with vehicle and identical conditions [20.93 6 1.69 mV, P < 0.01). Activity was increased compared to the positive control (forskolin, 21.65 6 1.78 mV), although this was not statistically significant ( Fig. 7A and 7B ).
CFTR Is Activated in the Absence of R-D Phosphorylation
PKA/cAMP-dependent phosphorylation of the CFTR R-D is a critical step in channel activation, but it has been previously demonstrated that flavonoid compounds (e.g., genistein 58 ) activate CFTR through a mechanism independent of PKA/cAMP-dependent phosphorylation. To examine whether resveratrol might activate CFTR via PKA-dependent pathways, cAMP levels and R-D phosphorylation were evaluated. Unlike the cAMP agonist forskolin, resveratrol had no measurable effect on the phosphorylation-dependent mobility shift of recombinant CFTR R-D and did not elevate cellular cAMP (Fig. 8) .
Resveratrol Increases CFTR Open Probability
Once we recognized that resveratrol did not activate CFTR via PKA-dependent pathways, patch clamp techniques were required to evaluate impact on CFTR channel open time. Segments of the apical plasma membrane sealed within the tip of a patch pipette were evaluated after application of test compounds to the intracellular surface in the excised, inside-out patch clamp configuration. In patches from apical membranes of MNSE cells, resveratrol stimulated an ;8 pS chloride channel consistent with CFTR potentiation in the absence of ATP and PKA. These experiments are the first to characterize single-channel CFTR in freshly isolated/low passage number sinonasal epithelia. Patches were excised and Fig. 6 . Resveratrol activates CFTR-mediated Cl 2 secretion in human sinonasal mucosa ex vivo. Representative Ussing chamber tracings of full-thickness human sinonasal tissue explants demonstrating robust activation of CFTR-dependent Cl 2 secretion with 100-mM resveratrol compared to DMSO controls (A). Ussing chamber summary data evaluating paired sinus mucosal samples from five individuals and demonstrating significant activation (P < 0.05) of ex vivo CFTR-dependent Cl 2 transport (B). (Adapted from Zhang et al. 54 ). CFTR 5 cystic fibrosis transmembrane conductance regulator; DMSO 5 Dimethyl sulfoxide. spontaneous activity recorded at 2Vcom 5 150 mV. Channel function was enhanced within seconds of administration of 100 mM resveratrol (Fig. 9A, upper   tracing) . This observation was validated in D060/ HEK293 cells expressing exogenous human WT-CFTR (Fig. 9A, lower tracing) . Under cell-free conditions, an increase in channel Po (rather than new channel insertion) was determined to account for CFTR activation. Complete inhibition of stimulated current by INH-172 further supports the finding that CFTR activity is amplified by resveratrol.
Open probability (NPo/N, where N represents channel number) was calculated from single-channel recordings following perfusion with 100-mM resveratrol and under control conditions. Open probability was significantly augmented following the application of resveratrol in MNSE cells (0.329 6 0.116 vs. 0.119 6 0.059 for control, P < 0.05). This result was confirmed in D060/ HEK293 cells expressing human WT-CFTR, where open probability was significantly increased compared to control (0.22 6 0.048 vs. 0.125 6 0.07, P < 0.05) (Fig. 9B) .
Resveratrol Activates Transepithelial Cl
2
Secretion in Hypoxic Cells and Reverses Hypoxia-Induced Reduction of ASL Depth
Following comprehensive evaluation of the Cl 2 secretagogue activity of resveratrol and its underlying mechanism of action, we next investigated the ability of the agent to compensate for the acquired defects in CFTR-mediated anion secretion demonstrated in hypoxic sinonasal epithelium. After 24 hours incubation in a hypoxic environment, MNSE and HSNE filters were With evidence that resveratrol activates CFTRmediated anion transport in cells that are deficient in the ability to secrete transepithelial Cl 2 due to acquired CFTR deficiency, we next assessed whether resveratrol mitigated the depleted ASL demonstrated in oxygenrestricted cultures. First, we established that Cl 2 secretagogue activity attributable to resveratrol would translate to hydration of ASL in epithelium compared to corresponding DMSO vehicle control in a normal oxygen environment. Resveratrol increased ASL depth in MNSE cultures after a 30-minute apical application (in lm: 8.08 6 1.68 vs. 6.11 6 0.47, DMSO control, P < 0.05, n 5 per condition) (Fig. 11) , indicating a robust treatment effect resulting from stimulation of apical Cl 2 secretion and enhanced CFTR channel Po. ASL hydration was significantly diminished by addition of the INH-172 (3.54 6 0.34, P < 0.05). INH-172 also suppresses constitutively activated CFTR, accounting for the overall decrease in ASL depth. The effects of drug were then measured on hypoxic MNSE and compared to the control solution. Hypoxia-induced abnormalities of fluid and electrolyte secretion in sinonasal epithelium were improved by a 30-minute application of resveratrol following 24 hours of hypoxia (5.55 6 0.74 vs. 3.13 6 0.17, n 5 per condition, P < 0.05), providing confirmation that the compound mitigates effects of acquired CFTR deficiency on depleted ASL (Fig. 12) .
DISCUSSION
The data presented in the current study suggests that a low oxygen environment profoundly affects normal ion transport physiology in both MNSE and HSNE and leads to acquired defects in CFTR-mediated transport. Although stimulation of transepithelial Cl 2 transport would be expected to hydrate the ASL, increased Na 1 absorption (as demonstrated in CF) reduces water content, leading to decreased clearance of dehydrated and eventually impacted mucus. 13 Notably, ENaC channels exhibited a time-dependent blockade, as detected by amiloride-dependent I SC in MNSE. Thus, both Na 1 absorption and Cl 2 secretion are reduced in the hypoxic murine model; an indication that the overall influence of hypoxia on the ASL could be mitigated by opposing effects on epithelial Na 1 and Cl 2 transport (with a net effect of diminished ASL depth, as measured in our experiments). HSNE exhibited a marked reduction in forskolin-stimulated I SC over 24 hours of low-oxygen exposure. In contrast to the murine situation, however, Na 1 absorption increased during the first 12 hours (as measured by amiloride blockade of ENaC). The finding that HSNE develops a globally decreased transepithelial Cl 2 secretion and increased Na 1 absorption in response to hypoxic conditions indicates that in human sinonasal mucosa, the detrimental effects on ion transport that impact ASL hydration (Cl 2 and HCO 3 2 secretion through CFTR; Na 1 absorption through ENaC) are compounded by tissue hypoxia. Thus, the ion transport properties are consistent with CF airway pathophysiology (decreased Cl 2 secretion and enhanced Na 1 absorption), resulting in dehydration of the ASL, and ultimately disrupted mucociliary transport.
CFTR activation has been shown to confer excellent therapeutic benefit in CF, a disease characterized by defective MCC. The drug ivacaftor has recently been Food and Drug Administration-approved for CF patients with at least one copy of the G551D mutation, but the agent is very expensive (approximately $300,000/year in the U.S.). 59 Recent studies have also shown that ivacaftor augments ASL depth, accelerates MCC, and pharmacologically reverses acquired CFTR dysfunction due to cigarette smoke exposure. 20 Given this precedent, resveratrol represents an excellent candidate for treatment of acquired Cl 2 transport defects based on an established safety profile, 60 activity equivalent to ivacaftor with regard to WT human CFTR stimulation, and well described antiinflammatory benefits. In addition, the working concentration of resveratrol was 100 mM, a drug concentration routinely achievable in topically applied, superperfused, or aerosolized solutions in human subjects in vivo. 61, 62 Single-channel patch clamp analysis indicates that the mechanism underlying resveratrol activity is CFTR channel potentiation; channel open probability increases with drug application, as demonstrated in both WT MNSE cells and a recombinant human CFTR expressing cell line. Resveratrol's conserved activity across several mammalian species also provides a means to study MCC activation in animal models (unlike ivacaftor, which has no effect on murine or porcine CFTR in primary nasal airway epithelium [data not shown]). 31 Because resveratrol is a robust CFTR channel potentiator in sinonasal epithelia, we hypothesized that the drug could ameliorate acquired CFTR dysfunction conferred by hypoxic incubation. The compound effectively stimulated transepithelial anion secretion in hypoxic epithelial cells and increased ASL thickness in both control and hypoxic monolayers, indicating that 1) the increase in hydration is most likely attributable to potentiating effects on CFTR channels; and 2) acquired CFTR dysfunction represents a therapeutic target that can be addressed 
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with resveratrol and/or other Cl 2 secretagogues. Activation that is independent of PKA provides additional evidence of direct CFTR binding of the compound, and the potentiating effects of the drug represent an optimal approach to directly stimulate CFTR, fluid and electrolyte transport, and ASL hydration. Because acquired defects of CFTR in chronic diseases such as sinusitis can result in both decreased channel expression and increased turnover in nasal airway epithelium, 63 potentiating CFTR channels already situated in the plasma membrane could serve as an effective strategy for reversing ASL dehydration in individuals with CRS.
CONCLUSION
Hypoxia-induced-acquired CFTR dysfunction can be ameliorated by resveratrol potentiation of CFTR channels, resulting in improved epithelial function. CFTR activation with Cl 2 secretagogues such as resveratrol represents an innovative approach to overcoming acquired CFTR defects in sinus and nasal airway disease. Additional studies to define the role of CFTR activation by resveratrol are indicated in CRS and could result in novel and improved therapeutic strategies for the disease.
